Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Mimedx Group Inc (MDXG)

Mimedx Group Inc (MDXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,096,217
  • Shares Outstanding, K 146,946
  • Annual Sales, $ 321,480 K
  • Annual Income, $ 58,230 K
  • EBIT $ 72 M
  • EBITDA $ 76 M
  • 60-Month Beta 1.94
  • Price/Sales 3.49
  • Price/Cash Flow 40.63
  • Price/Book 6.20

Options Overview Details

View History
  • Implied Volatility 40.01% ( +3.24%)
  • Historical Volatility 58.32%
  • IV Percentile 17%
  • IV Rank 15.33%
  • IV High 198.15% on 09/18/24
  • IV Low 11.37% on 08/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1,660
  • Volume Avg (30-Day) 207
  • Put/Call OI Ratio 2.20
  • Today's Open Interest 3,626
  • Open Int (30-Day) 3,542

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.07
  • Number of Estimates 1
  • High Estimate 0.07
  • Low Estimate 0.07
  • Prior Year 0.04
  • Growth Rate Est. (year over year) +75.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.59 +33.75%
on 10/23/24
7.67 -2.61%
on 11/11/24
+1.76 (+30.82%)
since 10/11/24
3-Month
5.47 +36.56%
on 10/10/24
7.67 -2.61%
on 11/11/24
+1.19 (+18.95%)
since 08/13/24
52-Week
5.47 +36.56%
on 10/10/24
9.27 -19.42%
on 12/20/23
+1.31 (+21.27%)
since 11/13/23

Most Recent Stories

More News
MIMEDX to Participate in Upcoming Investor Conferences

MDXG : 7.47 (+0.13%)
MiMedx: Q3 Earnings Snapshot

MiMedx: Q3 Earnings Snapshot

MDXG : 7.47 (+0.13%)
MIMEDX Announces Third Quarter 2024 Operating and Financial Results

MDXG : 7.47 (+0.13%)
MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30

MDXG : 7.47 (+0.13%)
MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue

MDXG : 7.47 (+0.13%)
MiMedx: Q2 Earnings Snapshot

MiMedx: Q2 Earnings Snapshot

MDXG : 7.47 (+0.13%)
MiMedx Group (NASDAQ: MDXG) Reports Q1 2023 Financial Results Showing 21.7% Sales Growth

MiMedx Group, Inc. (NASDAQ: MDXG) is engaged as a biotechnology company that is focused as a placental biologics developer to

MDXG : 7.47 (+0.13%)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

VCEL : 55.47 (-0.75%)
OCEL : 2.7500 (unch)
BRTX : 1.5400 (-6.10%)
MDXG : 7.47 (+0.13%)
NNVC : 1.3500 (unch)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

/PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs. The rising incidence of COPD is one...

OCEL : 2.7500 (unch)
BRTX : 1.5400 (-6.10%)
MDXG : 7.47 (+0.13%)
NNVC : 1.3500 (unch)
VCEL : 55.47 (-0.75%)
MIMEDX to Present at the Canaccord Genuity 42nd Annual Growth Conference

MARIETTA, Ga., Aug. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics...

MDXG : 7.47 (+0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. `Innovations in Regenerative Biomaterials` is the framework behind their mission to give physicians products and tissues to help the...

See More

Key Turning Points

3rd Resistance Point 7.80
2nd Resistance Point 7.67
1st Resistance Point 7.57
Last Price 7.47
1st Support Level 7.35
2nd Support Level 7.22
3rd Support Level 7.12

See More

52-Week High 9.27
Fibonacci 61.8% 7.82
Last Price 7.47
Fibonacci 50% 7.37
Fibonacci 38.2% 6.92
52-Week Low 5.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar